Herantis Pharma Plc · OMXHEX:HRTIS
Herantis Pharma — Investor Presentation (January 2023)
12 slides from Herantis Pharma's investor presentation, Jan 26, 2023
Slide 1: Company presentation
Company presentation Herantis Pharma is an innovative biotech company developing disease modifying therapies for Parkinson’s disease www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.
Slide 2: Forward-looking statement
Forward-looking statement This company presentation includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of
Slide 3: Herantis – at a glance
Herantis – at a glance Developing a disease-modifying therapy to Founded in Helsinki, Finland in 2008; address the unmet clinical need in Parkinson’s Listed at Nasdaq First North Helsinki disease and other neurodegenerative diseases Lead asset HER-096 is a small engineered Experienced board and mana
Slide 4: Herantis investment proposition
Herantis investment proposition • HER-096 has the potential to become a therapy for Parkinson’s disease Lead asset with a unique, disease modifying Mechanism of Action • Over 8 million patients globally (source: www.epda.eu.com) Market • Unmet need: no disease modifying therapies for Parkinson’s dis
Slide 5: HER-096: Disease-modifying therapy for Parkinson's disease
HER-096: Disese-modifying therapy for Parkinson’s disease PARKINSON’S DISEASE (PD) CURRENT TREATMENTS CANNOT OVER $10B MARKET • Degeneration of dopaminergic nerve cells in STOP THE PROGRESSION OF PD • Currently 8-10 million patients globally; mid brain cause severe motor and non-motor • For 50 years
Slide 6: HER-096 is a perfect drug candidate for Parkinson's disease
HER-096 is a perfect drug candidate for Parkinson’s disease (PD) • Designed based on the active site of the protein CDNF, a known ER protein and unfolded protein response (UPR) modulator HER-096 HER-096 • Neuroprotection, restores proteostasis and reduces neuroinflammation • Synthetic peptidomimetic
Slide 7: HER-096 has a unique multimodal disease modifying mechanism of action
HER-096 has a unique multimodal disease modifying mechanism of action 7 www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.
Slide 8: HER-096 improves motor function in mouse PD model
HER-096 improves motor function in mouse PD model (⍺-synuclein fibril model) Mouse bar test to observe motor coordination • Mouse walks from right to left CLICK BELOW TO SEE THE VIDEO ON YOUTUBE • Longer walking time corresponds to https://youtu.be/L3WmkhP2Opw compromised motor coordination • Video
Slide 9: HER-096 animal data confirm its unique MoA and brain penetration
HER-096 animal data confirm its unique MoA and brain penetration HER-096’s unique MoA confirmed HER-096 penetrates the brain in small and large in mouse PD model animals following a single subcutaneous injection Efficient brain penetration confirmed in mice, rats, and dogs HER-096 improves dopamin
Slide 10: Herantis strategy and achievements during 2022
Herantis strategy and achivements during 2022 • Create value in preclinical & early clinical development Strategy • Pursue partnering opportunities for HER-096 Encouraging preclinical efficacy and blood-brain barrier penetration Submission of clinical trial application (CTA) 2022 Selected for Europe
Slide 11: 2023 development milestones for HER-096
2023 development milestones for HER-096 Milestone Expected timing • Phase 1a clinical trial application (CTA) regulatory approval 1H 2023 • First HER-096 human dose in Phase 1a study • First HER-096 preclinical publication • Phase 1a read-out: Evidence of HER-096 safety and 2H 2023 blood-brain barri
Slide 12: Contact details
Contact details CEO Antti Vuolanto, [email protected] CFO Tone Kvåle, [email protected] www.herantis.com © 2014-2022 HERANTIS PHARMA Plc. All rights reserved.
Herantis Pharma — Investor Presentation (January 2023) on 6ix